Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease - Trial NCT06386497
Access comprehensive clinical trial information for NCT06386497 through Pure Global AI's free database. This phase not specified trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Insel Gruppe AG, University Hospital Bern
Timeline & Enrollment
N/A
Jun 01, 2024
Dec 31, 2025
Primary Outcome
Evaluation of acceptability and feasibility,Evaluation of acceptability and feasibility
Summary
This pilot study aims to evaluate the feasibility and acceptability of nocturnal
 translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two
 months in patients with Parkinson's Disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06386497
Device Trial